Association of High Serum Interleukin‐6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis

OBJECTIVE: The development of biomarkers to guide treatment decisions is a major research focus in rheumatoid arthritis (RA). Patients with RA have elevated interleukin‐6 (IL‐6) levels; however, the utility of IL‐6 as a predictor of treatment response is unclear. This study was undertaken to investi...

Descripción completa

Detalles Bibliográficos
Autores principales: Boyapati, Anita, Schwartzman, Sergio, Msihid, Jérôme, Choy, Ernest, Genovese, Mark C., Burmester, Gerd R., Lam, Gordon, Kimura, Toshio, Sadeh, Jonathan, Weinreich, David M., Yancopoulos, George D., Graham, Neil M. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496495/
https://www.ncbi.nlm.nih.gov/pubmed/32343882
http://dx.doi.org/10.1002/art.41299

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496495/
https://www.ncbi.nlm.nih.gov/pubmed/32343882
http://dx.doi.org/10.1002/art.41299

Ejemplares similares